**Hospira™ CEFOXITIN SODIUM POWDER FOR INJECTION**

**NAME OF THE MEDICINE**
Non proprietary name: cefoxitin sodium  
Molecular formula: $C_{16}H_{16}N_{3}NaO_{7}S_{2}$  
Molecular weight: 449.4  
Chemical Abstracts Service (CAS) registry number: 33564-30-6

**DESCRIPTION**
Hospira™ Cefoxitin Sodium Powder for Injection is a white to off white sterile powder of cefoxitin sodium for intravenous and intramuscular administration following reconstitution. Each vial contains cefoxitin sodium equivalent to 1 g of Cefoxitin.

Each gram of cefoxitin sodium contains approximately 51.2 mg (2.2 mEq) of sodium. The pH of 10% w/v cefoxitin sodium in Water for Injections is 4.2 to 7.0.

**PHARMACOLOGY**
Cefoxitin is a bactericidal antibiotic which acts by inhibiting bacterial cell wall synthesis. Due to the presence of a 7-α methoxy group in the β-lactam ring, it exhibits a high degree of stability in the presence of beta-lactamases.

**Microbiology**
Cefoxitin is active against the following microorganisms *in vitro*:

1. Aerobic bacteria  
   - Gram-positive cocci including *Staphylococci* (including coagulase-positive, coagulase-negative and penicillinase producing strains), Group A beta-haemolytic streptococci (*Streptococcus pyogenes*), Group B beta-haemolytic streptococci (*Streptococcus agalactiae*) and *Streptococcus pneumoniae* (*Diplococcus pneumoniae*). Other streptococci (most strains of enterococci, e.g. *Streptococcus faecalis*) are resistant.

2. Gram-negative cocci including *Neisseria gonorrhoeae* (including penicillinase-producing strains) and *Neisseria meningitidis*.

Anaerobic bacteria
1. Gram-positive cocci including *Peptococcus* spp, *Peptostreptococcus* spp and *Microaerophilic streptococcus*.
2. Gram-positive rods including *Clostridium perfringens*, *Clostridium* spp, *Eubacterium* spp and *Propionibacterium acnes*.
3. Gram-negative cocci including *Veillonella* spp.
4. Gram-negative rods including *Bacteroides fragilis*, *Bacteroides melaninogenicus*, *Bacteroides* spp (including both penicillin-susceptible and penicillin-resistant strains) and *Fusobacterium* spp.

Cefoxitin sodium is not active against pseudomonas spp, most strains of enterococci and many strains of *Enterobacter cloacae*. Methicillin-resistant staphylococci are almost uniformly resistant to cefoxitin sodium.

**Susceptibility testing**
For fast growing aerobic organisms, quantitative methods that require measurements of zone diameters give the most precise estimates of antibiotic susceptibility. One such procedure (Kirby-Bauer) has been recommended for use with discs to test susceptibility to cefoxitin. Interpretation involves correlation of the diameters obtained in the disc test with minimal inhibitory concentration (MIC) values for cefoxitin sodium.

Reports from the laboratory giving results of the standardized single disc susceptibility test using a 30 microgram cefoxitin disc should be interpreted according to the following criteria:

Organisms producing zones of 18 mm or greater are considered susceptible indicating that the tested organism is likely to respond to therapy.

Organisms of intermediate susceptibility produce zones of 15 to 17 mm indicating that the tested organism would be susceptible if high dosage is used or if the infection is confined to tissues and fluids (e.g. urine) in which high antibiotic levels are attained.

Resistant organisms produce zones of 14 mm or less indicating that other therapy should be selected.

The cefoxitin disc should be used for testing cefoxitin susceptibility.

Cefoxitin sodium has been shown by *in vitro* tests to have activity against certain strains of *Enterobacteriaceae* found resistant when tested with the cephalosporin class disc. For this reason, the cefoxitin disc should not be used for testing susceptibility to cephalosporins, and cephalosporin discs should not be used for testing susceptibility to cefoxitin sodium.

Dilution methods, preferably the agar plate dilution procedure, are most accurate for susceptibility testing of obligate anaerobes. A bacterial isolate may be considered susceptible if the MIC value for cefoxitin sodium is not more than 16 micrograms/mL. Organisms are considered resistant if the MIC is greater than 32 micrograms/mL.

Dilution or diffusion techniques – either quantitative (MIC) or breakpoint, should be used following a regularly updated, recognised and standardised method (e.g. Clinical and Laboratory Standards Institute (CLSI)). Standardised susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.
A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable.

A report of “Intermediate” indicates that the result should be considered equivocal, and if the microorganisms not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also requires a buffer zone, which prevents small-controlled technical factors causing major discrepancies in interpretation.

A report of “Resistant” indicates that the pathogen is not likely inhibited if the antimicrobial compound in the blood reaches concentrations usually achievable; other therapy should be selected.

Note: The prevalence of resistance may vary geographically for selected species and local information in resistance is desirable, particularly when treating severe infections.

**Pharmacokinetics**

Cefoxitin sodium administered by the parenteral route is excreted virtually unchanged by the kidneys. The mean terminal serum half life is approximately one hour and co-administration of probenecid will slow tubular excretion and increase and prolong blood levels. Although cefoxitin sodium will penetrate into the cerebrospinal fluid (CSF), concentrations are considerably lower than in the plasma.

Following **intravenous administration**, the peak serum concentration of cefoxitin sodium following 1 g infused intravenously over 3 minutes was 110.5 micrograms/mL, when infused over 30 minutes was 72 micrograms/mL, and when infused over 120 minutes was 25 micrograms/mL. Following 2 g infused intravenously over 3 minutes, the peak serum concentration was 221 micrograms/mL. The serum half life was approximately 50 minutes, falling to less than 1 microgram/mL at 4 hours.

In a number of studies using 0.5 g, 1 g, or 2 g intravenous doses of cefoxitin sodium, mean total urinary recovery ranged from 77% to 99% of the dose administered.

Following **intramuscular administration**, injections of 1 g of cefoxitin sodium in 0.5% lignocaine hydrochloride solution produced a peak serum concentration of approximately 30 micrograms/mL at 30 minutes, falling to approximately 3.2 micrograms/mL at 3 hours. Approximately 85% of an intramuscular dose is excreted by the kidneys in the first six hours resulting in high urine levels; for example, greater than 3000 micrograms/mL between one and two hours after a 1 g dose. When Hospira™ Cefoxitin Sodium Powder for Injection was reconstituted with 0.5% or 1% of lignocaine hydrochloride for intramuscular use, the local anaesthetic was found to have no effect on the absorption or elimination.

**INDICATIONS**

Hospira™ Cefoxitin Sodium Powder for Injection is indicated for the treatment of the following infections when due to susceptible organisms (see Microbiology) peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections.

Hospira™ Cefoxitin Sodium Powder for Injection has a high degree of stability against beta-lactamase and is therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. It can also be used in mixed infections provided that the organisms are sensitive to it.
Hospira™ Cefoxitin Sodium Powder for Injection can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscous perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes.

Hospira™ Cefoxitin Sodium Powder for Injection is also indicated for the prevention of post operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts.

CONTRAINDICATIONS
Hospira™ Cefoxitin Sodium Powder for Injection is contraindicated in persons who have shown hypersensitivity to cefoxitin sodium and the cephalosporin group of antibiotics.

Its use in patients with a history of hypersensitivity to penicillin requires great care (see PRECAUTIONS). Hospira™ Cefoxitin Sodium Powder for Injection is contraindicated in patients who have had a major allergic reaction to penicillin (anaphylaxis, angioneurotic oedema or urticaria).

Lignocaine hydrochloride should not be used as a diluent for intramuscular injection in patients who are hypersensitive to lignocaine.

PRECAUTIONS

Hypersensitivity reaction (allergic/anaphylaxis)
There is some clinical and laboratory evidence of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics, penicillins and cephalosporins. Severe reactions (including anaphylaxis) have been reported with most beta lactam antibiotics.

Before therapy with Hospira™ Cefoxitin Sodium for Injection, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics. Hospira™ Cefoxitin Sodium Powder for Injection should be given cautiously to penicillin allergic patients. If an allergic reaction occurs, the drug should be discontinued (see CONTRAINDICATIONS). Serious hypersensitivity reactions may require ADRENALINE (EPINEPHRINE) and other emergency measures.

Any patient who has demonstrated some form of allergy, particularly to drugs, should receive antibiotics cautiously.

Neonates
Solutions containing preservatives should not be used for injection or for flushing catheters in treating neonates. Benzyl alcohol as a preservative in Bacteriostatic Water for Injections has been associated with toxicity in neonates. Data are unavailable on the toxicity of other preservatives in this age group. Therefore, any diluent used with Hospira™ Cefoxitin Sodium Powder for Injection in the treatment of neonates should be free of any preservative.

The total daily dosage should be reduced when Hospira™ Cefoxitin Sodium Powder for Injection is administered to patients with transient or persistent reduction of urinary output due to renal insufficiency (see DOSAGE AND ADMINISTRATION) because high and prolonged serum antibiotic concentrations can occur from usual doses.

Concentrations of cefoxitin sodium in the CSF are considerably lower than in the plasma. Its use in the treatment of meningitis and brain abscess is therefore not advised.

Superinfection with non-susceptible organisms, including fungi, may occur and requires appropriate therapy.
Cefoxitin sodium appears to have little nephrotoxic potential in man at the usual doses. Patients whose clinical condition requires high doses, especially when potentially nephrotoxic drugs (e.g. aminoglycoside antibiotics) are administered concurrently, should be carefully monitored for renal function. Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.

Repeated use of lignocaine hydrochloride as a diluent for intramuscular use should be avoided in patients with severe liver disease or decreased hepatic blood flow, due to the possibility of lignocaine toxicity (resulting from decreased metabolism and accumulation).

**Clostridium difficile associated diarrhoea (CDAD)**

*Clostridium difficile* associated diarrhoea (CDAD) has been reported with nearly all antibacterial agents, including cefoxitin injection and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

Antibiotic associated pseudomembranous colitis has been reported with many antibiotics including cefoxitin sodium. Toxin produced by *Clostridium difficile*, appears to be the primary cause. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks –usually over two months after cessation of antibiotic therapy). Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against *Clostridium difficile* should be considered. Fluids, electrolytes and protein replacement should be provided when indicated. Drugs which delay peristalsis e.g. opiates and diphenoxylate with atropine (Lomotil) may prolong and/or worsen the condition and should not be used.

Antibiotics should be prescribed with care for patients with a history of gastrointestinal disease, especially ulcerative colitis, regional enteritis, or antibiotic associated colitis.

**Use in patients with impaired renal function:**

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. The total daily dose should be reduced when Hospira™ Cefoxitin Sodium Powder for Injection is administered to patients with transient or persistent reduction of urinary output due to renal impairment, because high and prolonged serum concentrations can occur in such individuals (see DOSAGE AND ADMINISTRATION).

Elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.

**Use in pregnancy**

*Category B1*: This category specifies drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformations or other direct or indirect harmful effects on the human foetus having been observed.

Studies in animals have not shown evidence of an increased occurrence of foetal damage. Hospira™ Cefoxitin Sodium Powder for Injection should not however be used in women of childbearing potential unless, in the judgement of the treating clinician, its use is deemed essential to the welfare of the patient and the expected benefits outweigh potential risks.
Use in lactation
Cefoxitin sodium is excreted in human milk. If possible, alternative arrangements should be made to feed the infant.

Prothrombin time
Prolonged prothrombin time may occur in patients receiving protracted antimicrobial therapy.

Effects on ability to drive and use machines
During treatment with Cefoxitin, undesirable effects may occur (e.g. hypotension) which may influence the ability to drive and use machines. Patients should be cautious when driving or operating machinery.

Interactions with other medicines
Cephalosporins have affected the stability of anticoagulant control of patients treated with phenindione and warfarin during one trial.

Concurrent treatment with nephrotoxic drugs such as gentamicin and frusemide may result in increased nephrotoxicity (see PRECAUTIONS).

Concomitant administration of oral probenecid competitively inhibits tubular secretion resulting in higher and more prolonged serum concentrations of cefoxitin sodium.

Interference with laboratory tests
A false-positive reaction to glucose in the urine may occur with reducing substances but not with the use of specific glucose oxidase methods.

Using the Jaffe Technique, falsely high creatinine values in serum may occur if cefoxitin sodium serum concentrations exceed 100 micrograms/mL. Serum samples from patients treated with cefoxitin sodium should not be analysed for creatinine if withdrawn within two hours of drug administration.

High concentrations of cefoxitin sodium in the urine may interfere with measurement of 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.

ADVERSE EFFECTS
Cefoxitin sodium is generally well tolerated. Adverse effects occurred in 8.5% of cases, were usually mild and transient, and rarely required cessation of treatment.

Local reactions:
Thrombophlebitis or phlebitis has occurred in 2.5% of cases following intravenous administration. Another 1.7% of cases reported pain in the infused vein and vein induration, erythema or exudates. Pain, induration and tenderness following intramuscular injections have been reported. Pain was often severe in cases where Hospira™ Cefoxitin Sodium Powder for Injection had been dissolved in Water for Injections instead of 0.5% lignocaine hydrochloride (see DOSAGE AND ADMINISTRATION).

Allergic:
Skin rashes, e.g. maculopapular rash and urticaria, occurred in 1.7% of cases. Other adverse effects included cutaneous vasculitis, pruritus, eosinophilia, fever and, rarely, other allergic reactions, including anaphylaxis which in rare cases has led to death.

Gastrointestinal:
Nausea, vomiting and diarrhoea have been reported rarely (see PRECAUTIONS).
Cardiovascular:
Hypotension.

Blood:
Eosinophilia, leukopenia, agranulocytosis, granulocytopenia, neutropenia, thrombocytopenia, haemolytic anaemia and bone marrow depression have been reported. Some individuals, particularly those with azotaemia, may develop positive direct Coombs tests during therapy with cefoxitin sodium.

Liver function:
Transient elevations in AST, ALT, serum LDH, and serum alkaline phosphatase have been reported. Jaundice has occurred.

Renal and Urinary Disorders:
Elevations in serum creatinine and/or blood urea nitrogen levels have been observed. As with the cephalosporins, acute renal failure has been reported rarely. The role of cefoxitin sodium in changes in renal function tests is difficult to assess, since factors predisposing to prerenal azotaemia or to impaired renal function usually have been present.

Other:
In addition to the adverse reactions listed above which have been observed in patients treated with cefoxitin, the following adverse reactions and altered laboratory test results have been reported for cephalosporins class antibiotics: Urticaria, erythema multiforme, Stevens-Johnson syndrome, serum sickness-like reactions, abdominal pain, colitis, renal dysfunction, toxic nephropathy, false positive test for urinary glucose, hepatic dysfunction including cholestasis, elevated bilirubin, aplastic anaemia, haemorrhage, prolonged prothrombin time, pancytopenia, agranulocytosis, superinfection, vaginitis including vaginitis candidiasis.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. (See DOSAGE AND ADMINISTRATION.) If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

DOSAGE AND ADMINISTRATION
Treatment
Hospira™ Cefoxitin Sodium Powder for Injection may be administered intravenously or intramuscularly (see reconstitution directions for each route below). Dosage and route of administration are determined by severity of infection, susceptibility of the causative organisms, and condition of the patient.

Therapy may be started while awaiting the results of susceptibility testing.

Adults: The usual adult dosage is 1 g or 2 g of cefoxitin sodium every 8 hours (see chart). In adults with renal insufficiency, an initial loading dose of 1 g to 2 g may be given. After a loading dose, the recommendations for maintenance dosage may be used as a guide.

In severe infections, the total daily dosage should not exceed 12 g per day.

Guidelines for dosage of Hospira™ Cefoxitin Sodium Powder for Injection

<table>
<thead>
<tr>
<th>Type of Infection</th>
<th>Dose</th>
<th>Frequency</th>
<th>Total Daily Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Uncomplicated 1 g Every 8 hours (occasionally every 6 hours) 3 g
Moderately severe or severe 2 g Every 8 hours (occasionally every 6 hours) 6 g
Infections generally needing antibiotics in higher dosage 3 g (2 g) Every 6 hours (Every 4 hours) 12 g

Maintenance dosage of Hospira™ Cefoxitin Sodium Powder for Injection in adults with reduced renal function

<table>
<thead>
<tr>
<th>Renal function</th>
<th>Creatinine Clearance (mL/min)</th>
<th>Dose</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild impairment</td>
<td>80 to 30</td>
<td>1 to 2 g</td>
<td>Every 8 to 12 hours</td>
</tr>
<tr>
<td>Moderate impairment</td>
<td>29 to 10</td>
<td>1 to 2 g</td>
<td>Every 12 to 24 hours</td>
</tr>
<tr>
<td>Severe impairment</td>
<td>&lt;10</td>
<td>0.5 to 1 g</td>
<td>Every 12 to 24 hours</td>
</tr>
<tr>
<td>Patients on dialysis*</td>
<td>&lt;5</td>
<td>0.5 to 1 g</td>
<td>Every 24 to 48 hours</td>
</tr>
</tbody>
</table>

* In patients undergoing haemodialysis, the loading dose of 1 to 2 g should be given after each haemodialysis, and the maintenance dose should be given as indicated in the table above. Monitoring of plasma levels is advised.

Uncomplicated gonorrhoea: For single dose therapy of uncomplicated gonorrhoea, including that caused by penicillinase producing strains, the recommended dose is 2 g of cefoxitin sodium intramuscularly given with 1 g of probenecid by mouth (at the same time or up to 1 hour before).

Neonates, infants and children: Neonates: 0 to 1 week of age, 20 to 40 mg/kg every 12 hours. 1 to 4 weeks of age, 20 to 40 mg/kg every 8 hours.

Dosage for premature infants not yet established.
Infants: (1 to 3 months) 20 to 40 mg/kg every 6 hours or every 8 hours.
Children: (over 3 months) 20 to 40 mg/kg every 6 hours or every 8 hours.

Cefoxitin sodium is not recommended for the therapy of meningitis. If meningitis is suspected, an appropriate antibiotic should be used.

In children with renal insufficiency, the dosage frequency should be reduced as indicated for adults.

**Prophylaxis**
For prophylactic use, the following doses are recommended:

Adults: 2 g administered intramuscularly approximately 1 hour before initial incision or intravenously just prior to surgery; then 2 g repeated twice at 6 hourly intervals.

Neonates, infants and children: There are no paediatric data on the prophylactic use of cefoxitin sodium. However, in view of its human efficacy and safety in this age group, the following doses are
Datasheet – New Zealand

proposed - in the case of infants and children 30 to 40 mg/kg doses may be given at the times
designated above. However, in neonates 30 to 40 mg/kg doses may be given approximately 1 hour
before initial incision and one further dose may be given after 8-12 hours.

Caesarean section patients: The first dose of 2.0 g is administered intravenously as soon as the
umbilical cord has been clamped. The second and third doses should be given as 2.0 g intravenously
or intramuscularly 4 hours and 8 hours after the first dose.

Administration

Intravenous administration: Warning For Neonates: Solutions containing preservatives should not
be used for injection or for flushing catheters in treating neonates. Benzyl alcohol as a preservative in
Bacteriostatic Water for Injections has been associated with toxicity in neonates. Data are
unavailable on the toxicity of other preservatives in this age group. Therefore, any diluent used with
Hospira™ Cefoxitin Sodium Powder for Injection in the treatment of neonates should be free of any
preservative.

Reconstitution: Reconstitute Hospira™ Cefoxitin Sodium Powder for Injection with Sterile Water
for Injections - 1 g is soluble in 2 mL. Although cefoxitin sodium is very soluble, for intravenous use
it is preferable to add 10 mL of Sterile Water for Injections to the 1 g vial. Shake to dissolve and then
withdraw entire contents of the vial into a syringe.

For direct intravenous injection, cefoxitin sodium may be slowly injected into the vein over a period
of 3 to 5 minutes or may be given through the tubing when the patient is receiving compatible
parenteral solutions.

Alternatively, an intermittent intravenous infusion of cefoxitin sodium may be employed when large
amounts of fluid are to be given. However, during infusion of the solution containing cefoxitin
sodium, it may be advisable temporarily to discontinue administration of any other infusion solution
at the same site (by using an appropriate IV infusion set).

A solution of cefoxitin sodium may also be given by continuous intravenous infusion (see
Compatibility information).

Intramuscular administration: Reconstitute Hospira™ Cefoxitin Sodium Powder for Injection 1 g
with 2 mL of 0.5% or 1% lignocaine hydrochloride (without adrenaline) solution. Some patients may
be hypersensitive to lignocaine (see ADVERSE EFFECTS). If lignocaine cannot be used,
Hospira™ Cefoxitin Sodium Powder for Injection may be reconstituted with 2 mL of Sterile Water
for Injections. Cefoxitin sodium is given by deep injection into a large muscle mass. Avoid injection
into a blood vessel.

Preparation of Solution:
The following table is provided for convenience in reconstituting Hospira™ Cefoxitin Sodium
Powder for Injection for both intravenous and intramuscular administration.

<table>
<thead>
<tr>
<th>Strength</th>
<th>Amount of Diluent to be Added (mL*)</th>
<th>Approximate Average Concentration (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 g vial</td>
<td>2 (IM)</td>
<td>400</td>
</tr>
<tr>
<td>1 g vial</td>
<td>10 (IV)</td>
<td>95</td>
</tr>
</tbody>
</table>

* Shake to dissolve and let stand until clear.

Product is for single use in one patient only
Compatibility information

The compatibility and stability of cefoxitin sodium in solution with the following series of frequently used intravenous infusion fluids and injectable additives have been established:

Sodium Chloride Intravenous Infusion 0.9%, Glucose Intravenous Infusion 5% or 10%, Glucose 5% with Sodium Chloride Intravenous Infusion 0.9%, Lactated Ringers Injection, Glucose 5% in Lactated Ringers Injection, Invert sugar 5% or 10% in water, Heparin 100 units/mL in Glucose 5% or Sodium Chloride Intravenous Infusion.

Hospira™ Cefoxitin Sodium Powder for Injection reconstituted to a concentration of 95 mg/mL or 400 mg/mL with Water for Injections, or Water for Injections preserved with benzyl alcohol, or Sodium Chloride Intravenous Infusion 0.9%, or Glucose Intravenous Infusion 5% strength or 10% strength should be used immediately after preparation. Any unused portion should be discarded.

To reduce microbiological hazard, use as soon as practicable after reconstitution. If storage is necessary, hold at 2 to 8°C for not more than 24 hours.

More dilute solutions of Cefoxitin 1 mg/mL or 40 mg/mL in Water for Injections, or Sodium Chloride Intravenous Infusion 0.9%, or Glucose Intravenous Infusion 5% strength or 10% strength, or Glucose 5% strength with Sodium Chloride Intravenous Infusion 0.9%, or Glucose 5% strength in Lactated Ringers Injection, or Lactated Ringers Injection, or Invert Sugar 5% strength or 10% strength in Water for Injections, or Heparin 100 u/mL in Glucose Intravenous Infusion 5% strength or Sodium Chloride Intravenous Infusion 0.9% should be used immediately after preparation. Any unused portion should be discarded.

To reduce microbiological hazard, use as soon as practicable after reconstitution. If storage is necessary, hold at 2 to 8°C for not more than 24 hours.

OVERDOSAGE

Expected effects would be those described under ADVERSE EFFECTS; namely, Allergic, Gastrointestinal, Blood, Liver function and Kidney.

In case of overdose, immediately contact the Poisons Information Centre for advice (In Australia, call 13 11 26. In New Zealand, call 0800 764 766).

PRESENTATION AND STORAGE CONDITIONS

White to off white powder, filled in 20 ml clear glass moulded Type 1 vial, sealed with a grey bromo butyl rubber stopper and flip-off seal

<table>
<thead>
<tr>
<th>Strength</th>
<th>Pack Size</th>
<th>ARTG No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospira™ Cefoxitin Sodium Powder for Injection equivalent to 1 g</td>
<td>5 vial</td>
<td>AUST R 168090</td>
</tr>
</tbody>
</table>

Store below 25°C. Protect from light.

NAME AND ADDRESS OF SPONSOR

New Zealand Sponsor:
Pfizer New Zealand Limited,
PO Box 3998
Auckland, New Zealand, 1140
Toll Free Number: 0800 736 363

**MEDICINE CLASSIFICATION**
Prescription Medicine

Date of Preparation: 22 February 2017